Cargando…

Beyond EGFR Targeting in SCCHN: Angiogenesis, PI3K, and Other Molecular Targets

Although the molecular landscape of squamous cell carcinoma of the head and neck (SCCHN) has been largely deciphered, only one targeted therapy has been approved to date without any molecular selection, namely cetuximab. Cetuximab is a monoclonal antibody targeting EGFR. It has been shown to improve...

Descripción completa

Detalles Bibliográficos
Autores principales: Saada-Bouzid, Esma, Le Tourneau, Christophe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6381014/
https://www.ncbi.nlm.nih.gov/pubmed/30815390
http://dx.doi.org/10.3389/fonc.2019.00074